Pharmacyte Biotech Inc (OTCMKTS:PMCB) stated that its CEO, Mr. Kenneth L. Waggoner, JD expressed his views on the company’s development plans and talked about the contribution of expert team in an article published in PharmaVOICE Magazine.
Mr. Waggoner stated that they are relying significantly on the advice of the team of three renowned physicians in oncology. They will be guiding in developing upcoming clinical trials targeting advanced pancreatic cancer. Also, they will contribute in the planning process of another trial. Working collaboratively, the expert advice of these three physicians has allowed company to design a strategy to deal with a severe unmet medical need for pancreatic cancer and has supported company in facing the hurdles in due course.
Uluru Inc (OTCMKTS:ULUR) Reports 2Q2015 Financial Results
Uluru Inc (OTCMKTS:ULUR) posted a net loss of $729,000 in 2Q2015 against a net loss of $710,000 in the same period last year. For the first two quarters completed June 30, 2015, the net loss was $1.47 million against a net loss of $1.58 million for the same period, a year earlier.
During 2Q2015 Uluru Inc released positive interim results for the pharmaco-economic assessment being performed in Europe. The company obtained marketing nod in Russia to initiate sales of Altrazeal®. Also, the company shipped the first order of Altrazeal® for Saudi Arabia and Egypt. The order of Saudi Arabia was partially completed during the second quarter. Kerry P. Gray, the CEO and President, said that company’s geographic expansion is going strong and with additional approvals, they expect more product launches in Europe, Russia, Asia and the Middle East.
DARA Biosciences Inc (NASDAQ:DARA) To Present At “Rodman and Renshaw Global Investment Conference”
DARA Biosciences Inc (NASDAQ:DARA) an oncology supportive care Pharma firm reported that it will be featured as a participating firm at the upcoming Rodman and Renshaw Global Investment Event to be held from September 8 to September 10, 2015.